Credit Suisse kept its target price for Everest Med (01952) at HK$80 and maintained its "outperform" rating.
The research house said it maintains the "outperform" rating given Everest's active BD deal performance in the past month and the encouraging potential the BD deals have brought in.
全新節目《說說心理話》青少年不可以戀愛！？真實個案講述驚心動魄經歷► 即睇
